| Project/Area Number |
25460193
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | University of the Ryukyus (2015)
Nagoya City University (2013-2014) |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KIMURA Kazunori 名古屋市立大学, 医学系研究科(研究院), 教授 (00423848)
ANDO Yuichi 名古屋大学, 医学部附属病院, 教授 (10360083)
MATSUNAGA Tamihide 名古屋市立大学, 医学系研究科(研究院), 教授 (40209581)
Ohmori Shigeru 信州大学, 医学部附属病院, 教授 (70169069)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2015: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2014: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2013: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
|
|---|
| Keywords | Rituximab / infusion reaction / monoclonal antibody / インフュージョンリアクション / 抗体医薬 / リツキシマブ / 分子標的薬 / 薬物相互作用 / モノクローナル抗体製剤 / マクロファージ |
|---|
| Outline of Final Research Achievements |
Rituximab also called RITUXAN can cause fever, a chill and the itch as adverse effects. This adverse effect sometimes could be severe, including fatal, infusion reaction (IR). Severe reactions typically occurred during the first infusion. In order to establish the method to avoid IR, risk factor of IR should be made clear. In this study, The patient who developed IR at Nagoya University hospital was 58.1% and at Nagoya City University hospital was 20.2％. The genomic DNA are picked out from blood of the patient who developed IR, and the responsible gene of a high-risk patient is being analyzed.
|
